Table 1. Characteristics of the Included Studies.

T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus; BM-HSCs: bone marrow hematopoietic stem cells; BM-MNCs: bone marrow mononuclear cells; MSCs: mesenchymal stem cells; UCB: umbilical cord blood; NA: not available; IV: intravenous; m: months

Regimen	Author And year	Country	Sample type	Sample size (cell therapy/ control)	Mean age (cell therapy /control)	Mean dose of injected cells	Mode of injection	Mean follow-up period
BM-HSC	Ye et al., 2017 [15]	China	T1DM	8 /10	18.86 /20.18	NA	IV	12 m
	Couri et al., 2009 [16]	Brazil	T1DM	23	18.4	10.52 × l06/kg	IV	29.8 m
	Voltarelli et al., 2007 [11]	Brazil	T1DM	15	19.2	11 × l06/kg	IV	18.8 m
BM-MNC	Bhansali et al., 2017 [17]	India	T2DM	10 /10	44.5 /53.5	1 ×109/kg	Superior pancreaticoduodenal artery	12 m
	Bhansali et al., 2009 [10]	India	T2DM	10	57.5	3.5 ×  108/kg	Superior pancreaticoduodenal artery	6 m
MSC	Bhansali et al., 2017 [17]	India	T2DM	10 /10	50.2 /53.5	1 × 106/kg	Superior pancreaticoduodenal artery	12 m
	Liu et al., 2014 [18]	China	T2DM	22	52.9	1 × 106/kg	IV on Day 5+ splenic artery on Day 10	12 m
	Carlsson et al., 2014 [19]	Sweden	T1DM	9 /9	24 /27	2.75  × l06/kg	IV	12 m
	Hu et al., 2013 [20]	China	T1DM	15 /14	17.6 /18.2	2.6 × 107/kg	IV	21 m
UCB	Giannopoulou et al., 2013 [12]	Germany	T1DM	7/ 10	3.02/ 6.6	1.27 × 106/kg	IV	12 m
	Tong et al., 2013 [21]	China	T2DM	3	41	2.88 × 106/kg	Intrapancreatic	6 m